Sarepta Therapeutics (SRPT) Posts Smaller-than-Expected Q3 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Sarepta Therapeutics (SRPT) PT Lowered to $168 at Piper Jaffray on 3Q Report; Lower Projected Enterprise Value Due to 'Eventual Cannibalization by DMD GeneRx'
October 25, 2018 7:54 AM EDTPiper Jaffray analyst Edward Tenthoff lowered the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $168.00 (from $189.00) while maintaining a Overweight rating, following the company's third quarter earnings report.
Analyst Tenthoff notes a lowered outlook on SRPT shares on a "lower projected enterprise... More
Sarepta Therapeutics (SRPT) PT Lowered to $190 at RBC Capital
October 25, 2018 7:30 AM EDTRBC Capital analyst Brian Abrahams lowered the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $190.00 (from $200.00) while maintaining a Outperform rating.
The analyst commented, "With Exondys 51 meeting expectations and the company continuing to execute on multiple clinical gene therapy and RNA development... More
